Circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A Dutch Uro-Oncology Study Group side-study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Budesonide; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 04 Oct 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
- 04 Oct 2016 Efficacy and safety results (n=227) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 20 Mar 2014 Not official study title and study status estimated.